Moderna/Merck positive mRNA cancer vaccine Phase 3 data lifts BioNTech on sector readthrough

 

• Merck and Moderna announced Phase 3 INTerpath-001 trial of mRNA-4157 (intismeran autogene) + Keytruda met primary RFS and secondary DMFS endpoints in resected melanoma.
• First positive late-stage mRNA cancer vaccine results validate individualized neoantigen approach heavily pursued by BioNTech.
• BNTX trading up ~11-14% in premarket on Aug 19 from Aug 18 close of $92.75, tracking massive MRNA surge (50%+) and MRK gains.
• BioNTech has advanced individualized mRNA cancer vaccines and bispecifics like pumitamig in its oncology pipeline, positioning it for similar potential.
• News validates mRNA oncology platform amid BNTX's post-earnings focus on shifting from COVID to cancer therapies.
• Analysts and investors see broad readthrough across mRNA cancer players following the landmark data.

https://finviz.com/stock?t=BNTX&p=d